
强生公司正在支持一家生物技术公司,该公司正在开发受迷幻药启发的药物,有望在不产生幻觉的情况下治疗抑郁症,领投了一轮1亿美元的融资,因为制药公司正日益拥抱一个曾经处于边缘的领域。
Johnson & Johnson is backing a biotech company developing psychedelic-inspired medicines that promise to treat depression without the hallucinations, leading a $100 million financing round as pharmaceutical companies increasingly embrace a once-fringe field.
作者:Madison Muller 和 Allison DeAngelis 这笔对私营公司 Delix Therapeutics Inc. 的投资,是通过强生的风险投资部门进行的,属于一轮超额认购的融资,由 SV Health Investors 旗下的 Dementia Discovery Fund 共同领投。Delix 表示,这笔资金将有助于推进其首个实验性抑郁症治疗药物于明年进入中阶临床试验。Delix 此前已筹集了1.15亿美元,但拒绝透露其估值。
By Madison Muller and Allison DeAngelis The investment in privately held Delix Therapeutics Inc., through J&J’s venture capital arm, was part of an oversubscribed funding round co-led by SV Health Investors’ Dementia Discovery Fund. The money will help advance Delix’s lead experimental depression treatment into mid-stage trials next year, the company said. Delix, which has raised $115 million in earlier rounds, declined to disclose its valuation.
这是大型药企对迷幻药潜在治疗益处的兴趣日益增长的最新迹象。据 Grand View Research 预测,迷幻药药物市场到2033年可能达到117亿美元。强生围绕 Spravato 建立了一个数十亿美元的业务,Spravato 是一种源自氯胺酮的鼻喷剂,用于治疗抑郁症。与必须在医疗监督下给药的 Spravato 不同,Delix 正在开发一种药丸,患者可以在家中服用,而不会经历迷幻之旅。
It’s the latest sign of big drugmakers’ growing interest in the potential therapeutic benefits of psychedelics. The market for psychedelic medicines could reach $11.7 billion by 2033, according to Grand View Research.J&J has built a multibillion-dollar business around Spravato, a ketamine-derived nasal spray for depression. Unlike Spravato, which must be administered under medical supervision, Delix is developing a pill that patients could take at home without experiencing a psychedelic trip.
这种方法反映了更广泛的努力,即利用这些药物的益处,同时消除幻觉和其他使其难以广泛给药的效应。该领域一直在吸引 AbbVie Inc. 和 Eli Lilly & Co. 等制药公司,甚至特朗普政府的新关注。
The approach reflects a broader push to harness benefits from the drugs while eliminating hallucinations and other effects that make them difficult to administer widely. The field has been attracting new attention from pharmaceutical companies like AbbVie Inc. and Eli Lilly & Co., and even the Trump administration.

“我认为对这一领域的兴趣从未如此之高,”Delix 首席执行官 Mark Rus 在接受采访时表示。Rus 曾在 Shire Plc 任职期间帮助推出了治疗 ADHD 的畅销药 Vyvanse,Shire Plc 后来被武田药品工业株式会社收购。
“I think interest in the space has never been higher,” Delix Chief Executive Officer Mark Rus said in an interview. Rus helped launch ADHD blockbuster Vyvanse while working for Shire Plc, which was later bought by Takeda Pharmaceutical Co.
Delix 的首款药物 zalsupindole 旨在刺激神经可塑性,即大脑在神经细胞之间形成和加强连接的能力。Rus 表示,他认为到 2030 年代,少数几家大型制药公司将在该领域拥有成功的业务。
Delix’s lead drug, zalsupindole, is designed to stimulate neuroplasticity, the brain’s ability to form and strengthen connections between nerve cells. Rus said he thinks a handful of large drug companies will have successful businesses in the area in the 2030s.
强生风险投资部门的一位发言人拒绝就对 Delix 的投资置评。
A spokesperson for J&J’s venture capital arm declined to comment on the Delix investment.
在一项涉及 18 名患者的小型早期研究中,服用 zalsupindole 的患者抑郁症状下降了约 50%,且改善效果在最后一次给药后持续了四周。该结果尚需在更大规模的安慰剂对照试验中得到确认。公司正在努力将结果发表在医学期刊上。
In a small, early-stage study of 18 patients, depression symptoms declined by about 50% among patients who tookzalsupindole, with improvements lasting four weeks after the final dose. The findings have yet to be confirmed in a larger, placebo-controlled trial. The company is working to publish the results in a medical journal.
Rus 表示,公司的目标人群是对传统抗抑郁药反应不佳的患者,传统抗抑郁药通常需要数周才能起效,且往往需要持续治疗。他表示,目标是为患者提供一种可在有限疗程内服用、而非无限期服用的治疗方案。
Rus said the company is targeting patients who haven’t responded well to conventional antidepressants, which can take weeks to work and often require ongoing treatment. The goal is to offer patients a treatment they can take for a limited period rather than indefinitely, he said.
有了这笔新融资,Delix 计划于 2027 年上半年启动一项包含 240 名患者的中阶段试验,测试为期一个月的每日给药和每周两次给药方案。结果预计将于 2028 年上半年出炉。
With the new funding, Delix plans to begin a mid-stage trial with 240 patients in the first half of 2027, testing daily and twice-weekly dosing over a month. Results are expected in the first half of 2028.
Rus 表示,Delix 还计划视市场状况和临床进展而定,探索明年上市的可能性。公司正在开发更多致幻剂启发化合物,并探索其在物质使用障碍、精神分裂症和神经退行性疾病(包括阿尔茨海默病和帕金森病)方面的潜力。
Rus said Delix also plans to explore the possibility of going public next year, depending on market conditions and clinical progress. The company is developing additional psychedelic-inspired compounds and exploring their potential in substance-use disorders, schizophrenia and neurodegenerative diseases, including Alzheimer’s and Parkinson’s.
行业出版物 Psychedelic Alpha 此前报道称,强生已与 Delix 签署条款清单,领投本轮融资。
Trade publication Psychedelic Alpha earlier reported that J&J had signed a term sheet with Delix to lead the financing round.